Help ?

IGMIN: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.

If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."

Discover the nexus of Science, Technology, Engineering, and Medicine in our Multidisciplinary Open Access Journal – a platform for breakthroughs and collaborative expertise, driving knowledge and innovation. | Important Update! Building on our inaugural year's success, adjustments to article processing charges will take effect in October. More details coming soon!

Abstract at IgMin Research

Our mission is to foster interdisciplinary dialogue and accelerate the advancement of knowledge across a wide spectrum of scientific domains.

Medicine Group Research Article Article ID: igmin187

Examining the Causal Connection between Lipid-lowering Medications and Malignant Meningiomas through Drug-target Mendelian Randomization Analysis

Pharmacology Molecular Medicine Affiliation



Objectives: This study aims to investigate the causal link between the use of statins, a type of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and the risk of developing malignant meningiomas, which are aggressive and recurrent tumors of the central nervous system with limited treatment options.
Methods: Using Mendelian Randomization (MR) analysis, the study explored the relationship between genetic variants related to the expression of lipid-lowering drug targets (HMGCR, PCSK9, NPC1L1, and APOB) and malignant meningiomas. The analysis utilized data from Genome-Wide Association Studies (GWAS) and expression quantitative trait loci (eQTL) databases, with a focus on the genetic homogeneity of the Finnish population. Instrumental variables for the MR analysis were derived from significant eQTLs for the mentioned drug targets.
Results: The MR analysis found a significant association between genetic variants linked to HMGCR inhibitor (statin) exposure and a reduced risk of malignant meningiomas. Specifically, an increased expression of the HMGCR gene in the blood was associated with lower susceptibility to malignant meningiomas (Odds Ratio [OR] = 2.57, 95% Confidence Interval [CI] = 1.05 - 6.31; p = 0.039). No significant associations were observed for other lipid-lowering drug targets.
Conclusion: Preliminary evidence suggests that statin use may lower the risk of developing malignant meningiomas, indicating a potential therapeutic benefit for managing this type of cancer. However, further research, including clinical trials, is necessary to confirm these findings and understand the mechanisms behind the protective effect of statins against malignant meningiomas.



    1. Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95. doi: 10.1093/neuonc/noac202. PMID: 36196752; PMCID: PMC9533228.
    2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9. PMID: 27157931.
    3. Harter PN, Braun Y, Plate KH. Classification of meningiomas-advances and controversies. Chin Clin Oncol. 2017 Jul;6(Suppl 1):S2. doi: 10.21037/cco.2017.05.02. Epub 2017 Jun 4. PMID: 28595423.
    4. Li Y, Drappatz J. Advances in the systemic therapy for recurrent meningiomas and the challenges ahead. Expert Rev Neurother. 2023 Jul-Dec;23(11):995-1004. doi: 10.1080/14737175.2023.2254498. Epub 2023 Sep 11. PMID: 37695700.
    5. Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, Buckner JC. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 2011 May;13(5):530-5. doi: 10.1093/neuonc/nor044. PMID: 21558077; PMCID: PMC3093340.
    6. Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. doi: 10.1200/JCO.2015.61.6490. Epub 2015 Nov 2. PMID: 26527781; PMCID: PMC4669593.
    7. Anderson TR, Slotkin TA. Maturation of the adrenal medulla--IV. Effects of morphine. Biochem Pharmacol. 1975 Aug 15;24(16):1469-74. doi: 10.1016/0006-2952(75)90020-9. PMID: 7.
    8. Vona R, Iessi E, Matarrese P. Role of Cholesterol and Lipid Rafts in Cancer Signaling: A Promising Therapeutic Opportunity? Front Cell Dev Biol. 2021 Mar 19; 9:622908. doi: 10.3389/fcell.2021.622908. PMID: 33816471; PMCID: PMC8017202.
    9. Ding X, Zhang W, Li S, Yang H. The role of cholesterol metabolism in cancer. Am J Cancer Res. 2019 Feb 1;9(2):219-227. PMID: 30906624; PMCID: PMC6405981.
    10. Mayengbam SS, Singh A, Pillai AD, Bhat MK. Influence of cholesterol on cancer progression and therapy. Transl Oncol. 2021 Jun;14(6):101043. doi: 10.1016/j.tranon.2021.101043. Epub 2021 Mar 20. PMID: 33751965; PMCID: PMC8010885.
    11. Vogel FCE, Chaves-Filho AB, Schulze A. Lipids as mediators of cancer progression and metastasis. Nat Cancer. 2024 Jan;5(1):16-29. doi: 10.1038/s43018-023-00702-z. Epub 2024 Jan 25. PMID: 38273023.
    12. Son M, Baek A, Sakkiah S, Park C, John S, Lee KW. Exploration of virtual candidates for human HMG-CoA reductase inhibitors using pharmacophore modeling and molecular dynamics simulations. PLoS One. 2013 Dec 30; 8(12):e83496. doi: 10.1371/journal.pone.0083496. PMID: 24386216; PMCID: PMC3875450.
    13. Xia XD, Peng ZS, Gu HM, Wang M, Wang GQ, Zhang DW. Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications. Front Cardiovasc Med. 2021 Oct 15; 8:764038. doi: 10.3389/fcvm.2021.764038. PMID: 34782856; PMCID: PMC8589637.
    14. Zhang R, Zeng J, Liu W, Meng J, Wang C, Shi L, Yang S, Chang J, Xing D. The role of NPC1L1 in cancer. Front Pharmacol. 2022 Aug 10; 13:956619. doi: 10.3389/fphar.2022.956619. PMID: 36034854; PMCID: PMC9399402.
    15. Behbodikhah J, Ahmed S, Elyasi A, Kasselman LJ, De Leon J, Glass AD, Reiss AB. Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. Metabolites. 2021 Oct 8;11(10):690. doi: 10.3390/metabo11100690. PMID: 34677405; PMCID: PMC8540246.
    16. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM, Davey Smith G, Gaunt TR, Haycock PC. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018 May 30; 7:e34408. doi: 10.7554/eLife.34408. PMID: 29846171; PMCID: PMC5976434.
    17. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyna M, Hingorani AD. Genetic drug target validation using Mendelian randomisation. Nat Commun. 2020 Jun 26;11(1):3255. doi: 10.1038/s41467-020-16969-0. PMID: 32591531; PMCID: PMC7320010.
    18. Wang K, Shi M, Huang C, Fan B, Luk AOY, Kong APS, Ma RCW, Chan JCN, Chow E. Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian randomisation analysis. Cardiovasc Diabetol. 2022 Sep 23;21(1):192. doi: 10.1186/s12933-022-01613-6. PMID: 36151532; PMCID: PMC9503210.
    19. Ueda M, Fukui K, Kamatani N, Kamitsuji S, Matsuo A, Sasase T, Nishiu J, Matsushita M. GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study. J Hum Genet. 2023 Oct;68(10):699-704. doi: 10.1038/s10038-023-01168-8. Epub 2023 Jun 13. PMID: 37308567.
    20. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, et al. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013 Nov;45(11):1274-1283. doi: 10.1038/ng.2797. Epub 2013 Oct 6. PMID: 24097068; PMCID: PMC3838666.
    21. Kurki MI. et al. editors. FinnGen: Unique genetic insights from combining isolated population and national health register data. medRxiv; 2022.
    22. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, Montgomery GW, Goddard ME, Wray NR, Visscher PM, Yang J. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016 May;48(5):481-7. doi: 10.1038/ng.3538. Epub 2016 Mar 28. PMID: 27019110.
    23. Burgess S, Thompson SG; CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011 Jun;40(3):755-64. doi: 10.1093/ije/dyr036. Epub 2011 Mar 16. PMID: 21414999.
    24. Chauquet S, Zhu Z, O'Donovan MC, Walters JTR, Wray NR, Shah S. Association of Antihypertensive Drug Target Genes with Psychiatric Disorders: A Mendelian Randomization Study. JAMA Psychiatry. 2021 Jun 1;78(6):623-631. doi: 10.1001/jamapsychiatry.2021.0005. PMID: 33688928; PMCID: PMC7948097.
    25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(7414):557-60. doi: 10.1136/bmj.327.7414.557. PMID: 12958120; PMCID: PMC192859.
    26. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017 May;32(5):377-389. doi: 10.1007/s10654-017-0255-x. Epub 2017 May 19. Erratum in: Eur J Epidemiol. 2017 Jun 29; PMID: 28527048; PMCID: PMC5506233.
    27. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018 May;50(5):693-698. doi: 10.1038/s41588-018-0099-7. Epub 2018 Apr 23. Erratum in: Nat Genet. 2018 Aug;50(8):1196. PMID: 29686387; PMCID: PMC6083837.
    28. Apra C, Peyre M, Kalamarides M. Current treatment options for meningioma. Expert Rev Neurother. 2018 Mar;18(3):241-249. doi: 10.1080/14737175.2018.1429920. Epub 2018 Jan 22. PMID: 29338455.
    29. Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW. Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg. 2010 Aug;113(2):202-9. doi: 10.3171/2010.1.JNS091114. PMID: 20225922.
    30. Bergner A, Maier AD, Mirian C, Mathiesen TI. Adjuvant radiotherapy and stereotactic radiosurgery in grade 3 meningiomas - a systematic review and meta-analysis. Neurosurg Rev. 2022 Aug;45(4):2639-2658. doi: 10.1007/s10143-022-01773-9. Epub 2022 May 11. PMID: 35543810.
    31. Drappatz J. How useful is chemotherapy for atypical and anaplastic meningiomas? Expert Opin Pharmacother. 2022 Oct;23(14):1559-1561. doi: 10.1080/14656566.2022.2131394. Epub 2022 Oct 5. PMID: 36189940.
    32. Ahmeti H, Caliebe A, Röcken C, Jansen O, Mehdorn MH, Synowitz M. Impact of peritumoral brain edema on pre- and postoperative clinical conditions and on long-term outcomes in patients with intracranial meningiomas. Eur J Med Res. 2023 Jan 21;28(1):40. doi: 10.1186/s40001-022-00962-y. PMID: 36670509; PMCID: PMC9862965.
    33. Combs SE, Edler L, Burkholder I, Rieken S, Habermehl D, Jäkel O, Haberer T, Unterberg A, Wick W, Debus J, Haselmann R. Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial. BMC Cancer. 2010 Nov 9; 10:615. doi: 10.1186/1471-2407-10-615. PMID: 21062428; PMCID: PMC2996393.
    34. Zeng Q, Shi F, Guo Z. Effectiveness of Postoperative Radiotherapy on Atypical Meningioma Patients: A Population-Based Study. Front Oncol. 2019 Jan 31; 9:34. doi: 10.3389/fonc.2019.00034. PMID: 30805304; PMCID: PMC6371043.
    35. Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019 Jan 18;124(2):328-350. doi: 10.1161/CIRCRESAHA.118.312782. PMID: 30653440.
    36. Costet P. Molecular pathways and agents for lowering LDL-cholesterol in addition to statins. Pharmacol Ther. 2010 Jun;126(3):263-78. doi: 10.1016/j.pharmthera.2010.02.006. Epub 2010 Mar 19. PMID: 20227438.
    37. Volpe M, Patrono C. The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. Eur Heart J. 2021 Nov 21;42(44):4518-4519. doi: 10.1093/eurheartj/ehab647. PMID: 34849717.
    38. Cai T, Abel L, Langford O, Monaghan G, Aronson JK, Stevens RJ, Lay-Flurrie S, Koshiaris C, McManus RJ, Hobbs FDR, Sheppard JP. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021 Jul 14; 374:n1537. doi: 10.1136/bmj.n1537. PMID: 34261627; PMCID: PMC8279037.
    39. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002 Apr;87(4):1451-8. doi: 10.1210/jcem.87.4.8412. PMID: 11932263.
    40. Gehring S, Tapia-Pérez JH, Kirches E, Firsching R, Keilhoff G, Schneider T, Mawrin C. Cytotoxic effects of statins and thiazolidinediones on meningioma cells. J Neurooncol. 2011 May;102(3):383-93. doi: 10.1007/s11060-010-0351-1. Epub 2010 Aug 30. PMID: 20803306.
    41. Seliger C, Meier CR, Becker C, Jick SS, Proescholdt M, Bogdahn U, Hau P, Leitzmann MF. Metabolic syndrome in relation to risk of meningioma. Oncotarget. 2017 Jan 10;8(2):2284-2292. doi: 10.18632/oncotarget.13667. PMID: 27903988; PMCID: PMC5356799.

Similar Articles

DNA Genetics and UHPLC-Q-TOF-MS Analysis of Phytochemicals for Asparagus racemosus Roots
Nguyen Thi Huong, Do Ngoc Thuy, Phung van Trung, Le Ngoc Hung and Mai van Nam
Diagnostic Challenges in Pancreatic Tumors
Ionuţ Simion Coman, Elena Violeta Coman, Costin George Florea, Teodora Elena Tudose, Cosmin Burleanu, Anwar Erchid and Valentin Titus Grigorean